-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $40

Benzinga·07/07/2026 16:03:23
Listen to the news
RBC Capital analyst Luca Issi maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and raises the price target from $35 to $40.